Truist analyst David MacDonald raised the firm’s price target on Guardian Pharmacy (GRDN) to $38 from $34 and keeps a Buy rating on the shares after its better-than-expected Q4 results and 2026 guidance raised. The company’s core organic trends remain strong, improved vaccine profitability provided a nice lift and the firm remains bullish on the development activity, with greenfield’s and recent M&A contributions running ahead of expectations, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRDN:
- Guardian Pharmacy Services Posts Strong Growth Amid Headwinds
- Guardian Pharmacy reports Q4 EPS 37c, consensus 27c
- Guardian Pharmacy backs FY26 revenue view of $1.40B-$1.42B, consensus $1.42B
- GRDN Upcoming Earnings Report: What to Expect?
- Guardian Pharmacy price target raised to $36 from $35 at Stephens